Last reviewed · How we verify
R21Matrix M
R21/Matrix M is a recombinant protein subunit malaria vaccine that elicits immune responses against the Plasmodium falciparum parasite.
R21/Matrix M is a recombinant protein subunit malaria vaccine that elicits immune responses against the Plasmodium falciparum parasite. Used for Malaria prevention in children and infants in endemic regions.
At a glance
| Generic name | R21Matrix M |
|---|---|
| Sponsor | London School of Hygiene and Tropical Medicine |
| Drug class | Recombinant protein subunit vaccine |
| Target | Plasmodium falciparum circumsporozoite protein (CSP) |
| Modality | Biologic |
| Therapeutic area | Infectious Disease / Immunology |
| Phase | Phase 3 |
Mechanism of action
R21/Matrix M combines the recombinant circumsporozoite protein (CSP) antigen R21 with the Matrix M adjuvant to stimulate both cellular and humoral immune responses against malaria parasites. The vaccine targets the pre-erythrocytic stage of the parasite lifecycle, preventing parasites from reaching and infecting liver cells. Matrix M is a saponin-based adjuvant that enhances the immunogenicity of the R21 antigen.
Approved indications
- Malaria prevention in children and infants in endemic regions
Common side effects
- Injection site pain or swelling
- Fever
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- R21Matrix M CI brief — competitive landscape report
- R21Matrix M updates RSS · CI watch RSS
- London School of Hygiene and Tropical Medicine portfolio CI